Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Aug 03, 2023 3:34pm
113 Views
Post# 35571923

RE:RE:RE:DRIP DRIP DRIP

RE:RE:RE:DRIP DRIP DRIP

As you know the new enrolment criteria  require a lot of screening and tests and research for each patient that will be selected for the trial!
What will be the ratio between  the number of patients selected vs  the number of patients referred 
Very low I expect thus very time consuming

juniper88 wrote: It shouldn't take long at all to restart the trial.  I remember Thera once stating that they would restart the trial by the end of June.  Unfortunately, something is amiss here and we, as usual, are being kept in the dark.  Is there a a technical reason?  Does the new agreement with Marathon have something to do with this?  

To those who thought that we might see some results by Oct 31st, at the rate we are going Thera might not even restart the trial by then.

<< Previous
Bullboard Posts
Next >>